Clinical features and prognosis of patients with acute non-specific chest pain in emergency and cardiology departments after the introduction of high-sensitivity troponins: a prospective cohort study

Nivethitha Ilangkovan,1 Hans Mickley,2 Axel Diederichsen,2 Annmarie Lassen,3 Thomas L Sørensen,4 Hussam Mahmoud Sheta,5 Peter B Stæhr,1 Christian Backer Mogensen6

ABSTRACT

Objectives To determine the incidence of clinical, cardiac-related endpoints and mortality among patients presenting to an emergency or cardiology department with non-specific chest pain (NSCP), and who receive testing with a high-sensitivity troponin. A second objective was to identify risk factors for the above-noted endpoints during 12 months of follow-up.

Design A prospective multicentre study.

Setting Emergency and cardiology departments in Southern Denmark.

Subjects The study enrolled 1027 patients who were assessed for acute chest pain in an emergency or cardiology department, and in whom a myocardial infarction or another obvious reason for chest pain had been ruled out. Patients were enrolled from September 2014 to June 2015 and followed for 1 year.

Main outcome measures Clinical, cardiac-related endpoints (cardiac-related death, acute myocardial infarction, unstable angina and coronary revascularisation) and all-cause mortality.

Results Over a period of 1 year, cardiac-related endpoints were found in 19 patients (1.9%): 0 patients experienced cardiac-related death, 2 (0.2%) had myocardial infarction, 4 (0.4%) had unstable angina pectoris and 17 (1.7%) underwent coronary revascularisation. All-cause mortality was observed in seven patients (0.7%). When compared with the general population, the standardised mortality ratio did not differ. The risk factors associated with the endpoints included male gender, body mass index >25 kg/m², previous known coronary artery disease, hypertension, hypercholesterolaemia, diabetes mellitus and the use of statins. A total of 73% of the endpoints occurred in males.

Conclusion The prognosis for patients with NSCP is favourable, with a 1-year mortality after discharge that is comparable with the background population. Few clinical endpoints took place during follow-up, and those that did were predominantly in males.

Strengths and limitations of this study

- No patients were lost to follow-up.
- Multicentre study enrolling patients from six hospitals.
- Few events during follow-up.
- The cohort was relatively unselected.
- The clinical endpoints were based on physician assessment and not otherwise validated.

INTRODUCTION

Patients with acute chest pain or discomfort represent a large proportion of referrals to emergency and cardiology departments. Although fewer than 20% of these patients are diagnosed with an acute myocardial infarction (MI),1–4 the absence of one does not rule out possible underlying coronary artery disease (CAD). CAD is associated with 20% of all deaths in Europe.5 Discharge diagnoses after an admission for acute chest pain include the clinical manifestations of CAD (unstable angina pectoris (UAP) or MI), other cardiac-related diagnoses (aortic dissection or pulmonary embolus), non-cardiac disorders (gastrointestinal, respiratory or musculoskeletal) and non-specific chest pain (NSCP). This latter group comprised patients who are discharged without a plausible explanation for their symptoms. While the former groups are well described in literature,6 7 patients with NSCP receive comparatively little attention, although they are not entirely ignored. Previous studies have noted that patients with NSCP have frequent contact with healthcare systems and high medication...
use. Other studies have revealed that 0.6%–0.8% of patients with NSCP who are seen in emergency department (ED) have a major cardiac event within 30 days of discharge.9 10

In this multicentre study, we examined patients who were discharged from an emergency or cardiology department with a diagnosis of NSCP after routine clinical care, including testing with a high-sensitivity troponin (hsTn). The principle objective was to describe the outcomes of patients with NSCP with respect to clinical, cardiac-related events and all-cause mortality during 1 year of follow-up. A second objective was to identify risk factors for predicting ischaemic cardiac events in the first year after discharge.

METHODS

Design

The study was structured as a prospective multicentre cohort study. Six hospitals in the Region of Southern Denmark participated: Aabenraa Hospital, Sonderborg Hospital, Odense University Hospital, Svendborg Hospital, Vejle Hospital and Kolding Hospital. The study enrolled consecutive patients admitted to emergency or cardiology departments with acute chest pain or discomfort. Patients received a routine physician evaluation that included testing with a hsTn assay.

Study population

The study included patients aged 30–70 years who were referred with chest pain to emergency or cardiology departments, and who had at least one hsTn measurement in the first 24 hours following admission. Patients were prospectively enrolled during a 9-month period from September 2014 to June 2015, and followed until June 2016 or for a minimum of 1 year, until emigration, or until death.

Patients were identified for study eligibility by searching daily through the central biochemical database, which stores laboratory results for patients in the Region of Southern Denmark. An hsTn T value <14 ng/L or an hsTn I value <25 ng/L was required for inclusion. The attending physician’s discharge diagnosis was recorded, and patients were considered to have NSCP if any of the following international diagnosis code (International Classification of Diseases 10 (ICD-10) codes) were given: DR072 (precordial chest pains), DR073 (other chest pains), DZ034 (observation for MI) or DZ035 (observation for coronary disease). A structured phone interview was completed within 3 days of discharge.

Patients were excluded from the study if they were not contacted within 3 days of discharge (after three calls were made on different days and at different times), if they did not understand either Danish or English, if they were intoxicated, if they were pregnant, if they had an obvious cause for their chest pain or discomfort or if they had normal coronary angiography during the index admission. Additionally, patients were excluded from the study if they did not provide consent for follow-up or if medical records from their index admission were unavailable.

Material and data

A phone interview was conducted by the first author or by one of the two nurses who participated in the study. Patients received standardised questions pertaining to symptoms that they had at the time of index contact, as well as questions regarding their medical history and their risk factors for CVD. The study questionnaire was validated for interobserver validity, with a finding of 72% agreement between interviewers. Following the interview, patients were mailed a consent form requesting access to their health records, which contained clinical, laboratory and imaging results.

Definitions

Smoking was quantified in pack years, with one pack year defined by 20 cigarettes, per day, per year. Hypertension, hypercholesterolaemia and diabetes were self-reported conditions. Family history was considered positive if any first degree relative, regardless of age, had known CVD. Statins were identified using the Anatomical Therapeutic Chemical code C10AA.

The medical history was established using ICD-10 diagnoses from admissions that occurred in the 10 years preceding the index visit. Subsequently, these were grouped into clinical categories: prior CAD included the ICD-10 diagnoses for acute and chronic ischaemic heart disease; peripheral arterial disease (PAD) included the diagnostic codes for intermittent claudication and atherosclerotic disease; ischaemic cerebral disease included the codes for apoplexy and transitory cerebral ischaemia and supraventricular tachycardia included the codes for atrial fibrillation and atrial flutter.

Since comorbidity is a recognised confounding variable for CVD, Charlson comorbidity index scores were calculated for participants.11 12 This was done using the primary discharge diagnosis from admissions that occurred in the 10 years prior to the index visit. The diagnosis specified by the attending physician at the time of admission(s) was the recorded primary discharge diagnosis; this was not validated by a chart review or other means.

Data on prescription medications were obtained using information accessed from the Odense Pharmacoepidemiologic Database.13 Patients were considered to have used a statin if they had filled a prescription for one in the 3 months before the index admission.

Clinical outcomes

The primary outcome was a composite endpoint of all-cause mortality and clinical cardiac-related endpoints. Patients were classified as having a clinical cardiac-related endpoint if any of the following occurred during the year of follow-up: cardiac death, acute MI, UAP, or coronary revascularisation.

The endpoints were identified using information collected from the National Patient Register14 and the
Civil Registration System, which included diagnostic codes entered by attending physicians.

**HsTn assays**
The study used the hsTn assays hsTnI or hsTnT, both with a 99th percentile cut-off point. Odense University Hospital used hsTnI, which was analysed by Abbot Diagnostics Architect with an upper reference limit of 25 ng/L. The 10% coefficient of variation (CV) was 5 ng/L and the MI decision limit was ≥25 ng/L. All other participating hospitals used hsTnT, which was analysed by Roche Diagnostic Elecsys 2010, modular analytics E170, Cobas e411 and Cobas e601. The 99th percentile cut-off value was 14 ng/L, the 10% CV 13 ng/L and the MI decision limit was ≥14 ng/L.

**Sample size calculations**
With a sample of 1298 patients, the study had a power of 80% and a two-sided CI of 95% for identifying risk factors that occurred 20% more frequently in patients with the pre-specified outcomes of all-cause mortality and clinical, cardiac-related endpoints. We assumed that clinical outcomes would occur in 2% of patients who were unexposed to the risk factors of interest, and in 5% of patients who were exposed to the risk factors.

**Statistics**
Continuous variables were organised into categorical subgroups, with the exception of age, which was reported in medians with interquartile ranges. Receiver-operating characteristic curves were calculated for each variable to identify acceptable cut-off points. Categorical variables were reported in frequency and percentages, and the Pearson’s χ² test was used to make intergroup comparisons. Any unobtained laboratory data were analysed as missing data.

Patients were followed until the first clinical endpoint occurred. Unadjusted event data were shown as a failure plot. The prognostic effect of variables on the clinical endpoints was analysed by univariate cox regression. Continuous variables were tested than reported, but all significant variables were reported, in addition to select, clinically relevant, non-significant variables. A P value <0.05 was considered significant.

From Statistics Denmark, we obtained population size and mortality among people aged 30–70 years living in the Region of Southern Denmark in 2015. We used this information to calculate the expected mortality ratio for the study population. The observed mortality ratio in the NSCP study population was then compared with the expected mortality ratio, and adjusted for age and gender to estimate the standardised mortality ratio in the study sample compared with the general population. Data were analysed using STATA v.14.2 (Stata, College Station, Texas).

Written, informed consent to access records was sent to participants after their phone interviews and confirmed prior to accessing their records.

**RESULTS**

Among 1213 eligible patients, 1027 returned their consent forms and were included in the study. Figure 1 shows the flow chart for patient inclusion and exclusion. Patients who were eligible for study and completed the interview, but did not return their consent, are referred to as non-participants. A comparison between participants (n=1027) and non-participants (n=186) showed a significant difference in median age and gender: the median age for participants was 54 years (IQR: 47–62) versus 47 years (IQR: 39–56) for non-participants, P=0.001; females comprised 568 (55%) of participants and 90 (48%) of non-participants, P=0.081. Two patients left Denmark before the end of the follow-up period.

Baseline characteristics for the participants are shown in table 1. Patients with a clinical endpoint were significantly older with a median age of 61 (IQR: 47–62), were predominantly male (73%), had a Charlson score ≥1, used a statin and had more vascular comorbidity at baseline compared with patients who did not experience a clinical endpoint.

Table 2 lists study outcomes after 30 days and 1 year. At the 30-day follow-up, all-cause mortality was zero (0%, 95% CI: 0% to 0.3%), two participants had an MI (0.2%, 95% CI: 0% to 0.5%), none had UAP (0%, 95% CI: 0% to 0.3%) and four underwent coronary revascularisation (0.4%, 95% CI: 0.01% to 0.8%). The 30-day composite endpoint of all-cause mortality and clinical, cardiac-related endpoints was experienced by five patients (0.5%, 95% CI: 0.1% to 0.9%).

At the 1-year follow-up, a total of seven patients in the cohort had died (0.7%, 95% CI: 0.2% to 1.2%). Compared with the general population, the standardised mortality ratio was 1.2 (95% CI: 0.5 to 2.4). The number of patients with clinical, cardiac-related endpoints was 19 (1.9%; 95% CI: 1.0% to 2.7%). During this study period, no cardiac-related death was observed (0%, 95% CI: 0% to 0.3%), 2 patients (0.2%, 95% CI: 0% to 0.5%) had an MI, 4 patients (0.4%, 95% CI: 0.01% to 0.1%) experienced UAP and 17 patients (1.7%; 95% CI: 0.9% to 2.4%) underwent coronary revascularisation. In total, 26 patients had 30 events, such that the composite endpoint of all-cause mortality and clinical, cardiac-related endpoints occurred in 26/1027 patients (2.5%, 95% CI 1.6% to 3.5%). A total of 19 (73%) of these composite endpoints occurred in male patients. The difference became more distinct with time, as demonstrated in the accumulated endpoints plot (figure 2), and depicted over the total length of the study (1.4 years).

Table 3 shows the HR for risk factors and outcomes after 1 year, as well as the CI for all clinical events, cardiac-related events and all-cause mortality. Whereas a univariate analysis was performed, a multivariate analysis was omitted due to the lack of clinical events. Variables significantly associated with clinical events included gender, a body mass index (BMI) >25 kg/m², a Charlson score >1, pre-existing CAD, combined ischaemic comorbidity (a

Open Access

Figure 1  Flow chart for inclusion of study patients. CD, cardiology department; ED, emergency department; hsTn, high-sensitivity troponin.

patients with NSCP represent nearly 25% of all patients.

DISCUSSION
Prognosis for patients with NSCP
Patients with NSCP attract relatively little research attention. However, in this cohort study of 4289 patients, patients with NSCP represented nearly 25% of all patients.

composite value that included CAD, ischaemic cerebral disease and PAD), hypertension, hypercholesterolaemia, diabetes and the use of statins. Of note, cholesterol laboratory values could not be obtained for 15% of study participants.
Table 1  Descriptive baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total n=1027 (%)</th>
<th>No clinical endpoint n=1001 (%)</th>
<th>At least one clinical endpoint n=26 (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>568 (55)</td>
<td>561 (56)</td>
<td>7 (27)</td>
<td>0.003</td>
</tr>
<tr>
<td>Male</td>
<td>459 (45)</td>
<td>440 (44)</td>
<td>19 (73)</td>
<td></td>
</tr>
<tr>
<td><strong>Median age (IQR), years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30–39</td>
<td>54 (47–62)</td>
<td>54 (47–62)</td>
<td>61 (53–66)</td>
<td>0.010</td>
</tr>
<tr>
<td>40–49</td>
<td>247 (24)</td>
<td>243 (24)</td>
<td>4 (15)</td>
<td>0.020</td>
</tr>
<tr>
<td>50–59</td>
<td>325 (32)</td>
<td>319 (32)</td>
<td>6 (23)</td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>353 (34)</td>
<td>337 (34)</td>
<td>16 (62)</td>
<td></td>
</tr>
<tr>
<td><strong>Charlson score</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>783 (76)</td>
<td>770 (77)</td>
<td>13 (50)</td>
<td>0.001</td>
</tr>
<tr>
<td>≥1</td>
<td>244 (24)</td>
<td>231 (23)</td>
<td>13 (50)</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous smoker</td>
<td>338 (33)</td>
<td>334 (33)</td>
<td>4 (15)</td>
<td>0.002</td>
</tr>
<tr>
<td>Current smoker</td>
<td>257 (25)</td>
<td>243 (24)</td>
<td>14 (54)</td>
<td></td>
</tr>
<tr>
<td>Never smoked</td>
<td>432 (42)</td>
<td>424 (43)</td>
<td>8 (31)</td>
<td></td>
</tr>
<tr>
<td><strong>Statin use</strong></td>
<td>213 (21)</td>
<td>202 (20)</td>
<td>11 (42)</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Cardiovascular comorbidity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>166 (16)</td>
<td>156 (16)</td>
<td>10 (39)</td>
<td>0.002</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>19 (2)</td>
<td>16 (2)</td>
<td>3 (12)</td>
<td>0.001</td>
</tr>
<tr>
<td>Ischaemic cerebral disease</td>
<td>49 (5)</td>
<td>47 (5)</td>
<td>2 (8)</td>
<td>0.479</td>
</tr>
<tr>
<td>Supraventricular tachycardia</td>
<td>53 (5)</td>
<td>51 (5)</td>
<td>2 (8)</td>
<td>0.554</td>
</tr>
</tbody>
</table>

P values are for $\chi^2$ test between patients with and without a clinical endpoint.

Table 2  Endpoints at the 30-day and 1-year follow-up

<table>
<thead>
<tr>
<th></th>
<th>30 days n=5</th>
<th>1 year n=26</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Death</strong></td>
<td>0 0 (0.0–0.3)</td>
<td>7 0.7 (0.2–1.2)</td>
</tr>
<tr>
<td>Cardiac-related death</td>
<td>0 0 (0.0–0.3)</td>
<td>0 0.0 (0.0–0.3)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>2 0.2 (0.0–0.5)</td>
<td>2 0.2 (0.0–0.5)</td>
</tr>
<tr>
<td>Unstable angina pectoris</td>
<td>0 0 (0.0–0.3)</td>
<td>4 0.4 (0.0–0.8)</td>
</tr>
<tr>
<td>Revascularisation</td>
<td>4 0.4 (0.1–0.8)</td>
<td>17 1.7 (0.9–2.4)</td>
</tr>
<tr>
<td>Composite endpoint</td>
<td>5 0.5 (0.1–0.9)</td>
<td>26 2.5 (1.6–3.5)</td>
</tr>
</tbody>
</table>

Figure 2  Failure plot with combined endpoints for the total cohort.
studies reinforce the notion that when clinical events do
occur, they tend to do so soon after discharge.10

In contrast, other studies have contracted our find-
ings. Jordan et al9 found that patients with NSCP had an
increased risk of cardiac events after discharge. Of note,
this study did not impose an age limitation, the definition
of cardiovascular events included a greater number of
diagnoses (such as stroke and periphery arterial disease)
and the follow-up time was longer (up to 5.5 years). More
importantly, it is unclear where enrolled patients had a
normal troponin, and the type of troponin assay would
have been markedly different from what is currently used
since the inclusion period for this study was from 2002
to 2009. Similarly, Bandstein et al demonstrated a higher
 event rate for MI when compared with our study. In a
cohort of patients aged more than 25 years who presented
to the ED with chest pain and had a single hsTn T <14,
1.2% (146/12 033) of patients experienced an MI in
the year after the index visit.20 The difference between
this study and our own could be explained by age differ-
ces between the cohorts.21 Finally, Kelly and Klim22
found that patients who presented to the ED with chest
pain, but who had a normal ECG and normal troponins,
had a mortality rate of 3% after a median follow-up of
48 months. In addition, during this time frame 0.6% of
the cohort had an MI and 3.1% underwent revascularisa-
tion. Qualifying these findings was again the fact that the
cohort was different. Specifically, the cohort was younger,
excluded individuals with known CAD and was 55% male.
Furthermore, the study employed an older generation of
troponin assay when compared with the hsTn used in our
study.

Risk factors for future cardiac-related events among the NSCP
with NSCP
To our knowledge, this is the first study to assess risk
factors in NSCP after hsTn implementation. Our study
demonstrated that the following variables influence the
1-year risk of a cardiac event: male gender, BMI >25 kg/ m²,
known CAD, other vascular comorbidity, hypertension,
hypercholesterolaemia, diabetes mellitus and the
use of statins. A total of 73% of the composite endpoints
occurred in males, confirming existing knowledge
that male gender is a significant risk factor for CAD.
Not surprisingly, most cardiovascular risk stratification
tools, such as the Systematic Coronary Risk Evaluation
(SCORE), already include gender as a variable in their
scoring systems.23

Omstedt et al9 showed that the risk of a future MI,
unplanned revascularisation and death in patients with
NSCP are associated with age, previous MI, heart failure,
hypertension, stroke, hyperlipidaemia, diabetes mellitus
and male gender. These risk factors were recognised in
our study. Nejatian et al’s study10 showed that admitted
patients had a worse prognosis than directly discharged
patients. However, admitted patients had a greater
number of cardiovascular risk factors, thereby demonstr-
ating that the clinical assessment remains a critical
element of chest pain assessment, and that hsTn cannot
be considered a stand-alone test when attempting to rule
out acute MI.

Strength and limitations
The strength in our study is that it was a multicentre
study with prospective data collection. Moreover,
outcome data were obtained from national registration

Table 3 HR for exposure variables and endpoints during
1 year of follow-up

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All clinical events (n = 26)</th>
<th>Clinical, cardiac-related endpoint (n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40+</td>
<td>1.0 (0.3–3.5)</td>
<td>1.0 (0.3–3.5)</td>
</tr>
<tr>
<td>50+</td>
<td>3.4 (1.6–14.0)</td>
<td>4.7 (1.0–19.7)</td>
</tr>
<tr>
<td>BMI &gt;25 kg/m²</td>
<td>1.7 (0.4–7.0)</td>
<td>1.1 (0.2–8.3)</td>
</tr>
<tr>
<td>Charlson score ≥ 1</td>
<td>3.2 (1.5–6.9)</td>
<td>1.9 (0.7–4.8)</td>
</tr>
<tr>
<td>Smoking &gt;12 package years</td>
<td>1.9 (0.8–5.3)</td>
<td>2.1 (0.8–5.3)</td>
</tr>
<tr>
<td>Alcohol &gt;2 U/week</td>
<td>0.8 (0.4–1.7)</td>
<td>0.9 (0.3–2.1)</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>3.3 (1.5–7.3)</td>
<td>3.8 (1.5–9.5)</td>
</tr>
<tr>
<td>Ischaemic cerebral disease</td>
<td>1.7 (0.4–7.0)</td>
<td>1.1 (0.2–8.3)</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>7.4 (2.2–24.5)</td>
<td>3.1 (0.4–23)</td>
</tr>
<tr>
<td>Supraventricular tachycardia</td>
<td>1.5 (0.4–6.4)</td>
<td>1.0 (0.2–7.6)</td>
</tr>
<tr>
<td>Combined ischaemic comorbidity*</td>
<td>4.0 (1.9–8.7)</td>
<td>3.6 (1.5–8.9)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5.2 (2.1–12.8)</td>
<td>5.8 (1.9–17.5)</td>
</tr>
<tr>
<td>Hypercholesterolaemia</td>
<td>2.5 (1.1–5.9)</td>
<td>6.0 (1.7–20.6)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5.0 (2.2–11.6)</td>
<td>5.2 (2.0–13.7)</td>
</tr>
<tr>
<td>Family history of CVD</td>
<td>1.7 (0.7–3.8)</td>
<td>1.6 (0.6–4.0)</td>
</tr>
<tr>
<td>Triglycerides ≥1 mmol/L</td>
<td>1.4 (0.5–3.8)</td>
<td>1.0 (0.4–2.7)</td>
</tr>
<tr>
<td>Total cholesterol &gt;5 mmol/L</td>
<td>0.5(2.1–2.1)</td>
<td>0.4 (0.2–1.1)</td>
</tr>
<tr>
<td>LDL &gt;3 mmol/L</td>
<td>0.5 (0.2–1.1)</td>
<td>0.3 (0.1–1.0)</td>
</tr>
<tr>
<td>HDL &lt;1 mmol/L</td>
<td>2.1 (0.8–5.5)</td>
<td>3.0 (1.1–8.5)</td>
</tr>
<tr>
<td>Statin use</td>
<td>2.8 (1.3–6.2)</td>
<td>4.3 (1.8–10.6)</td>
</tr>
</tbody>
</table>

*Combined ischaemic comorbidity consists of coronary artery disease, ischaemic cerebral disease and peripheral vascular disease.
BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

unplanned revascularisation and 0.2% died.9 The
second study, a Swedish population-based study that
was conducted after implementation of an hsTn assay,9
found that 30 days after ED discharge 0.3% of patients
with NSCP had experienced an MI, 0.3% had undergone
 coronary revascularisation and 0.2% had died. These
studies reinforce the notion that when clinical events do
occur, they tend to do so soon after discharge.10
systems that are linked to individual civil registration numbers.\textsuperscript{14,15} However, our study does have some limitations. First, the cohort excluded patients who had a coronary angiography performed during index contact. We chose to exclude these patients as clearly the evaluating physician suspected CAD rather than NSCP. UAP, which was one of the study’s cardiac-related endpoints, is a clinician-dependent diagnosis and carries the risk of misclassification of patients that should have a diagnosis of NSCP. Second, 186 patients did not return their consent, the reasons for which were unexplored and hence unclear. Third, we only included patients aged 70 years as it is known that increasing age is an important risk factor for CAD. This could partially explain the difference in findings between our study and other studies, as most other studies did not have an upper age limit.\textsuperscript{9,10,20} Finally, the main study limitation was the lack of events that occurred during follow-up; unfortunately, this restricted our ability to study risk factors. While a sample size was calculated before beginning the study, the outcome rates from existing literature overestimated the expected outcome rate.

This study demonstrates that patients with NSCP have a good prognosis, with very few patients at risk of death or a clinical, cardiac-related endpoint. The lack of endpoints may help clinicians reassure patients with NSCP, thereby reducing patient anxiety and the risk of readmission. Future research could focus on patients with NSCP using the risk factors identified in this study, or alternatively they could focus on how to reduce the frequency of NSCP patient visits to emergency and cardiology departments.

CONCLUSION

Our study demonstrates that patients with NSCP have a good prognosis on discharge. Among NSCP patients with cardiac-related endpoints, male gender is a significant risk factor for an adverse outcome among patients with a BMI $>$25 kg/m$^2$, a history of CAD or another vascular comorbidity, hypertension, hypercholesterolaemia, diabetes mellitus and who use statins. Patients who are discharged from the hospital after an initial assessment for acute chest pain, without further investigation, are usually evaluated correctly and can be reassured of a positive prognosis.

Author affiliations

1Department of Cardiology, Hospital of Southern Denmark, Aabenraa, Denmark
2Department of Cardiology, Odense University Hospital, Odense, Denmark
3Department of Emergency Medicine, Odense University Hospital, Odense, Denmark
4Department of Internal Medicine, Hospital of Southern Denmark, Sonderborg, Denmark
5Department of Medical Research, Odense University Hospital, Svendborg, Denmark
6Department of Emergency Medicine, Hospital of Southern Denmark, Aabenraa, Denmark
7Department of Emergency Medicine, Kolding Hospital for his daily search of troponin values. We want to thank the following hospitals for their collaboration during this study: Emergency Department and Cardiology Department, Hospital of Southern Denmark; Emergency Department and Cardiology Department, Kolding and Vejle Hospital; Emergency Department and Cardiology Department, Odense University Hospital, Odense and Svendborg.

Contributors The steering committee (NI, HM, AL, AD, CBM) designed the study. NI and CBM obtained funding. NI and CBM analysed the data. All authors (NI, HM, AL, AD, CBM, PBS, TLS, HMS) contributed to the interpretation and revision of the manuscript. All authors (NI, HM, AL, AD, CBM, PBS, TLS, HMS) can take responsibility for the integrity of the data and the accuracy of the data analysis, contributed to the implementation of the study, helped with data interpretation and approved the final report for publication.

Funding This study was funded by the Region of Southern Denmark, Hospital of Southern Denmark, The University of Southern Denmark, and Knud and Edith Eriksen memory foundation.

Competing interests None declared.

Patient consent Obtained.

Ethics approval According to the Regional Scientific Ethical Committees for Southern Denmark, the study did not require ethics clearance (confirmed by email 18 March 2014). The study was registered with The Danish Data Protection Agency (2008-4133-573/1 allowing access to discharge diagnosis from the charts).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


